Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBRM1 | Q86U86 | 17/20 | 0.36 |
| ▸ | SMARCA2 | P51531 | 15/20 | 0.36 |
| ▸ | SMARCA4 | P51532 | 15/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 8/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.34 |
| ▸ | IKBKB | O14920 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29619378 | 0.87 | PBRM1 (0.44) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL30552520 | 0.82 | PBRM1 (0.39) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL27053152 | 0.82 | PBRM1 (0.38) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL24461256 | 0.82 | PBRM1 (0.39) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL30552430 | 0.82 | PBRM1 (0.39) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL29072084 | 0.82 | SMARCA2 (0.49) | PBRM1SMARCA2SMARCA4 | |
| SCHEMBL29619449 | 0.82 | SMARCA2 (0.49) | PBRM1SMARCA2SMARCA4 | |
| SCHEMBL24461303 | 0.76 | SMARCA2 (0.45) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL31505611 | 0.71 | JAK3 (0.40) | PBRM1SMARCA2SMARCA4NR1I2 | |
| SCHEMBL31505584 | 0.71 | SMARCA2 (0.37) | PBRM1SMARCA2SMARCA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024488-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024488-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | PBRM1 18/4885SMARCA2 14/4885SMARCA4 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.